"10.1371_journal.pone.0078511","plos one","2013-11-06T00:00:00Z","Elijah R Behr; Marylyn D Ritchie; Toshihiro Tanaka; Stefan Kääb; Dana C Crawford; Paola Nicoletti; Aris Floratos; Moritz F Sinner; Prince J Kannankeril; Arthur A M Wilde; Connie R Bezzina; Eric Schulze-Bahr; Sven Zumhagen; Pascale Guicheney; Nanette H Bishopric; Vanessa Marshall; Saad Shakir; Chrysoula Dalageorgou; Steve Bevan; Yalda Jamshidi; Rachel Bastiaenen; Robert J Myerburg; Jean-Jacques Schott; A John Camm; Gerhard Steinbeck; Kris Norris; Russ B Altman; Nicholas P Tatonetti; Steve Jeffery; Michiaki Kubo; Yusuke Nakamura; Yufeng Shen; Alfred L George; Dan M Roden","Cardiovascular Sciences and Genetics Research Centers, St George’s University of London, London, United Kingdom; Departments of Medicine, Molecular Physiology and Biophysics, Pediatrics, and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Pennsylvania State University, Eberly College of Science, The Huck Institutes of the Life Sciences, University Park, Pennsylvania, United States of America; Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan; Department of Medicine I, University Hospital Munich, Ludwig-Maximilians-University Munich, Munich, Germany; Department of Biomedical Informatics, Columbia University, New York, New York, United States of America; Heart Failure Research Center, Department of Clinical and Experimental Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Institute for Genetics of Heart Diseases, Department of Cardiovascular Medicine, University Hospital Münster; Institut National de la Santé et de la Recherche Médicale, UMRS 956, University Pierre et Marie Curie, Univ Paris 06, Paris, France; Department of Medicine (Cardiology), University of Miami Miller School of Medicine, Miami, Florida, United States of America; Drug Safety Research Unit, Southampton, United Kingdom; Institut National de la Santé et de la Recherche Médicale, UMR1087, CNRS UMR 6291, Université de Nantes and CHU Nantes, Nantes, France; Center of Cardiology at Hospital of Starnberg, Starnberg, Germany; Department of Bioengineering, Stanford University, Palo Alto, California, United States of America; Department of Biomedical Informatics, Columbia University, New York, New York, United States of America; University of Chicago, Chicago, Illinois, United States of America; RIKEN Center for Genomic Medicine, Yokohama, Japan; Deutsches Zentrum für Herz-Kreislauf-Forschung e.V., partner site Munich Heart Alliance, Munich, Germany; IZKF of the University of Münster, Münster, Germany; Department of Physiology, University of Miami Miller School of Medicine, Miami, Florida, United States of America; Department of Molecular and Cellular Pharmacology and Hussman Institute of Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, United States of America","Conceived and designed the experiments: EB SK PJK AAMW CB ES-B SZ PG NB YJ JJS AJC GS ALG DMR. Performed the experiments: EB TT SK MS PJK AAMW CB ES-B SZ PG NB VM SS CD SB YJ RB RM JJS AJC GS KN MK DMR. Analyzed the data: EB MDR TT DC PN AF YJ RBA NT SJ MK YN YS DMR. Contributed reagents/materials/analysis tools: MDR TT RBA NT MK YN YS. Wrote the paper: EB MDR ALG DMR.","The authors have the following interests. AAMW is a member of the scientific advisory board of Sorin. RJM reports consultancy for Sanofi-Aventis, GSK, and Boston Scientific. He reports various expert testimonies not related to the present study. He was paid for lectures by Sanofi-Aventis and Boston Scientific. Travel and accommodations have been paid by Sanofi-Aventis. He is chair of DSMB of a multicenter study co-supported by the National Heart, Lung, and Blood Institute, and Medtronic, GE, and Zoll. AJC has acted as a consultant for Sanofi, Servier, Daiichi, Boehringer Ingelheim, Bayer, Novartis, Gilead and Menarini. He is a member of DSMB for studies funded by Servier, Novartis, BMs and Pfizer. ALG reports additional funding to his institution by Gilead Sciences to study proprietary compounds, but unrelated to the present study. Together with DMR he holds U.S. Letters Patent No. 6,458,542, issued October 1, 2002 for Method of Screening for Susceptibility to Drug-Induced Cardiac Arrhythmia. For this particular study the DARE samples were genotyped at Gene Expression Ltd. Further support was provided by a collaboration with the International Serious Adverse Events Consortium, whose membership currently includes Abbott, Amgen, Astra-Zeneca, Cerner, Daiichi-Sankyo, GlaxoSmithKline, Merck, Novartis, Pfizer, Takeda, and the Welcome Trust. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","11","Elijah R Behr","ERB",34,TRUE,15,24,14,4,TRUE,TRUE,FALSE,0,NA,FALSE
